Seek Returns

BBIO vs. ILMN: BridgeBio Pharma vs. Illumina Stock Comparison

How do BridgeBio Pharma (BBIO) and Illumina (ILMN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BridgeBio Pharma (BBIO) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Company profile comparison for BridgeBio Pharma (BBIO) and Illumina (ILMN)
Profile ItemBBIOILMN
NameBridgeBio Pharma Inc.Illumina Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization14.47 billion USD32.23 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 27, 2019July 28, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BBIO
ILMN
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BridgeBio Pharma (BBIO) and Illumina (ILMN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BridgeBio Pharma (BBIO) and Illumina (ILMN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Total Return (1Y)22.70%79.70%
Total Return (3Y, Annualized)40.97%28.16%
Total Return (5Y, Annualized)8.25%-10.65%

Risk Profile

Drawdown History

BBIO
ILMN
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BridgeBio Pharma (BBIO) and Illumina (ILMN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Volatility (1Y, Annualized)44.39%48.47%
Beta (5Y)0.931.46
Max Drawdown (5Y)-89.79%-82.95%
Avg. Volume (3M)2.68M2.77M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BBIO and ILMN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Sharpe Ratio (1Y)0.411.56
Sortino Ratio (1Y)0.632.25

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Illumina (ILMN) earns 32.39% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): BBIO does not report ROE, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
ROE (TTM)--32.39%
ROA (TTM)-13.97%8.32%
Net Margin (TTM)-59.84%19.72%
Operating Margin (TTM)-3.30%20.02%
Gross Margin (TTM)94.34%67.68%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Illumina (ILMN) at -0.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BridgeBio Pharma (BBIO) nor Illumina (ILMN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Revenue Growth (YoY)126.26%-0.66%
Revenue Growth (3Y CAGR)86.30%-1.78%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Illumina (ILMN) carries debt-to-equity ratio of 0.74 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): BBIO does not report debt-to-equity ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Current Ratio (MRQ)2.092.63
Debt / Equity (MRQ)--0.74
Net Debt / EBITDA--0.85

Dividends

Dividend Yield (TTM)

Neither BridgeBio Pharma (BBIO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BridgeBio Pharma (BBIO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): BBIO does not report P/E ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Illumina (ILMN) reports 10.30, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BridgeBio Pharma (BBIO) vs. Illumina (ILMN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BridgeBio Pharma (BBIO) and Illumina (ILMN)
MetricBBIOILMN
P/E Ratio (TTM)--36.68
P/S Ratio (TTM)15.317.10
P/B Ratio (MRQ)-5.5910.30
Free Cash Flow Yield (TTM)-1.98%2.67%